
Product Data Sheet

Product Name: Siltuximab
Cat. No.: GC68336

Chemical Properties

Cas. No. 541502-14-1

Formula M.Wt 144.98 kDa

Solubility Storage Store at -80°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Siltuximab is an anti-**IL-6 (interleukin-6)** monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research^{[1][2][3]}.

Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model^[1].

Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model^[4].

Animal Model: Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells^[1]

Dosage: 10 mg/kg

Administration: Intraperitoneal injection; 10 mg/kg; 3 times per week

Result: Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal Model: Female NOD-SCID mice with MCF-7 tumor^[4]

Dosage: 20 mg/kg

Administration: Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks

Result: Blocked MCF-7 engraftment, induced regressions in 90% of tumors.

[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. *Prostate*. 2011 Sep 15;71(13):1455-65.

[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. *Thorax*. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.

[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. *J Thorac Oncol*. 2014 Jul;9(7):974-982.

[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor- α -positive breast cancer. *Breast Cancer (Dove Med Press)*. 2016 Feb 3;8:13-27.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA